[Federal Register Volume 80, Number 191 (Friday, October 2, 2015)]
[Notices]
[Page 59764]
[FR Doc No: 2015-25010]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 12551-008]

Salvatore & Michelle Shifrin; Mansfield Hollow Hydro, LLC; Notice
of Transfer of Exemption

    1. By letter filed November 26, 2014, and supplemented on July 23,
2015, Mansfield Hollow Hydro, LLC (Mansfield Hydro) informed the
Commission that the exemption from licensing for the Mansfield Hollow
Hydroelectric Project No. 12551, had been transferred to Mansfield
Hydro.\1\ The project is located on the Natchaug River in Tolland
County, Connecticut.
---------------------------------------------------------------------------

    \1\ O'Connell Energy Group made the filing on behalf of
Mansfield Hydro, which is owned by O'Connell Development Group, Inc.
---------------------------------------------------------------------------

    2. The exemption was originally issued to Salvatore and Michelle
Shifrin (Shifrins) on June 17, 2009.\2\ The November 26, 2014 letter
gave notice that the Shifrins had leased the right to operate the
project to Mansfield Hydro. The July 23, 2015 filing contained a copy
of the lease showing that all project lands and facilities were also
leased to Mansfield Hydro, with exception of the five 100-kilowatt
turbines, which Mansfield Hydro owns.
---------------------------------------------------------------------------

    \2\ 127 FERC ] 62,216, Order Granting Exemption From Licensing
(5 MW or Less) (2009).
---------------------------------------------------------------------------

    3. The transfer of an exemption does not require Commission
approval. Thus, the Shifrins' lease of project properties and operating
rights to Mansfield Hydro effectively transferred the exemption to
Mansfield Hydro.
    4. Mansfield Hydro is the exemptee of the Mansfield Hollow
Hydroelectric Project No. 12551. The exemptee's contact is: Stephen
Fisk, General Manager, Mansfield Hollow Hydro, LLC, c/o O'Connell
Energy Group, 57 Suffolk Street, Suite 200, Holyoke, MA 01040.

    Dated: September 25, 2015.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2015-25010 Filed 10-1-15; 8:45 am]
 BILLING CODE 6717-01-P


January 29, 2004 MEMORANDUM SUBJECT: Science Chapter on: Environmental Fate Studies and Environmental Fate Assessment of Phenol.

FROM A. Najm Shamim, Ph. D., Chemist Regulatory Management Branch II Antimicrobials Division ( 7510C)

To: Ben Chambliss, Acting Team Leader Regulatory Management Branch II Antimicrobials Division ( 7510C)

And Tim McMahon, Ph. D., Chairman of ADTC Committee Antimicrobials Division ( 7510C)

And Michelle Centra, Toxicologist, and Member of ADTC Regulatory Management Branch II Antimicrobials Division( 7510C)

And A. Najm Shamim, Ph. D., Science Coordinator for Phenol RED Regulatory Management Branch II Antimicrobials Division ( 7510C)

Thru: Connie Welch, Chief Regulatory Management Branch II Antimicrobials Division ( 7510C)

Environmental Fate Science Chapter and Fate Assessment on Phenol is submitted for Reregistration Eligibility Decision ( RED). EXECUTIVE SUMMARY Environmental Fate Assessment:

Phenol appears to have degradation pathways in air ( calculated half life less than a day) water ( measured half life less than a day), aerobic and anaerobic soils ( degradation half lives less than 5 days). It is not likely to bioaccumalate in aquatic organisms. ( Measured BCF in goldfish is 0.28 and 1.3 in golden orfe). Data on plants show that due to a high respiratory decomposition of phenol into carbondioxide ( mineralization), it is also not likely to accumulate in plants. Due to multi media degradation pathways, phenol is not likely to be an environmental concern. Appendix Environmental Fate Science Chapter For Phenol:

Phenol is registered with OPP as an active product and is used as an intermediate in the production of epoxy resins, the production of various other products, as a general disinfectant and in medicinal preparations. For the reregistration eligibility decision ( RED) process the Agency has relied on open literature and fate properties of Phenol obtained from open literature. The following fate properties were obtained from an open literature search. 1, 2, 3 1. Vapor Pressure: 0.3513 mm Hg1; 0.341 mm Hg2 2. Henry law Constant ( air/ water partition coefficent): 4.0 x 10 7 m3/ mole 3. Log K OC ( organic carbon ratio in soil): 1.21 1.96 4. Log K OW ( octanol/ water partition coefficient): 1.46 5. Absorbs light in the region of 290 330 nm, may photodegrade directly in surface water. 6. Half life in freshwater < 1 day. 7. Biodegrades completely in soil within 5 days. 8. Estimated half life for gas phase reaction of phenol with photochemically produced hydroxyl radicals is 0.61 days ( Overall half life < 1 day). 9. Log bioconcentration factor ( BCF) is 0.28 in goldfish and 1.3 for golden orfe.

Phenol is not expected to bioaccumulate in plants, even though plants readily absorb phenol, because of the high respiratory decomposition rate of phenol to CO 2. Phenol does not pose concerns to aquatic organisms due to the low BCF and the rapid biodegradation in water.

Surface Water and Ground Water Contamination:

Phenol's use in the production of resins and other manufacturing industries, pulp mills, wood treatment facilities, and as a general disinfectant allows for the possibility of ground and surface water contamination. Despite phenol's high water solubility and poor sorption to soil, biodegradation of phenol is sufficiently rapid so that the probability of groundwater contamination will be low. Because phenol absorbs light in the region 290 330 nm, phenol might photodegrade directly in surface water. Phenol is not expected to absorb to sediment in the water column.

BIBLIOGRAPHY 10. Hazard Substances Databank ( HSDB), A Database of the National Library of Medicine's TOXNET System. 11. " Health and Environmental Effects Profile for Phenol." ( 1987) MRID # NR437332 01. U. S. EPA 12. " Toxicological Profile for Phenol." ( 1998) Agency for Toxic Substance and Disease Registry. U. S. Department of Health and Human Services.


[Federal Register Volume 88, Number 238 (Wednesday, December 13, 2023)]
[Notices]
[Pages 86328-86329]
[FR Doc No: 2023-27336]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER24-560-000]

Carpenter Wind Farm LLC; Supplemental Notice That Initial Market-
Based Rate Filing Includes Request for Blanket Section 204
Authorization

    This is a supplemental notice in the above-referenced proceeding of
Carpenter Wind Farm LLC's application for market-based rate authority,
with an accompanying rate tariff, noting that such application includes
a request for blanket authorization, under 18 CFR part 34, of future
issuances of securities and assumptions of liability.
    Any person desiring to intervene or to protest should file with the
Federal Energy Regulatory Commission, 888 First Street NE, Washington,
DC 20426, in accordance with Rules 211 and 214 of the Commission's
Rules of Practice and Procedure (18 CFR 385.211 and 385.214). Anyone
filing a motion to intervene or protest must serve a copy of that
document on the Applicant.
    Notice is hereby given that the deadline for filing protests with
regard to the applicant's request for blanket authorization, under 18
CFR part 34, of future issuances of securities and assumptions of
liability, is December 27, 2023.
    The Commission encourages electronic submission of protests and
interventions in lieu of paper, using the FERC Online links at http://www.ferc.gov. To facilitate electronic service, persons with internet
access who will eFile a document and/or be listed as a contact for an
intervenor must create and validate an eRegistration account using the
eRegistration link. Select the eFiling link to log on and submit the
intervention or protests.
    Persons unable to file electronically may mail similar pleadings to
the Federal Energy Regulatory Commission, 888 First Street NE,
Washington, DC 20426. Hand delivered submissions in docketed
proceedings should be delivered to Health and Human Services, 12225
Wilkins Avenue, Rockville, Maryland 20852.
    In addition to publishing the full text of this document in the
Federal Register, the Commission provides all interested persons an
opportunity to view and/or print the contents of this document via the
internet through the Commission's Home Page (http://www.ferc.gov) using
the ``eLibrary'' link. Enter the docket number excluding the last three
digits in the docket number field to access the document. At this time,
the Commission has suspended access to the Commission's Public
Reference Room, due to the proclamation declaring a National Emergency
concerning the Novel Coronavirus Disease (COVID-19), issued by the
President on March 13, 2020. For assistance, contact the Federal Energy
Regulatory Commission at [email protected] or call toll-free,
(886) 208-3676 or TTY,<PHONE_NUMBER>.
    The Commission's Office of Public Participation (OPP) supports
meaningful public engagement and participation in Commission
proceedings. OPP can help members of the public, including landowners,
environmental justice communities, Tribal members and others, access
publicly available information and navigate Commission

processes. For public inquiries and assistance with making filings such
as interventions, comments, or requests for rehearing, the public is
encouraged to contact OPP at<PHONE_NUMBER> or [email protected].

    Dated: December 7, 2023.
Kimberly D. Bose,
Secretary.
[FR Doc. 2023-27336 Filed 12-12-23; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 77, Number 191 (Tuesday, October 2, 2012)]
[Notices]
[Pages 60125-60126]
[FR Doc No: 2012-24326]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2012-N-1006]

Generic Drug Facilities, Sites and Organizations

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of Requirement.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is notifying generic
drug facilities, and certain sites and organizations identified in a
generic drug submission, that they must provide identification
information to FDA. This information is required to be submitted to the
FDA annually under the Generic Drug User Fee Act Amendments of 2012
(GDUFA) included in the Food and Drug Administration Safety and
Innovation Act (FDASIA). This notice is intended to help organizations
ascertain if they need to self-identify with the FDA, determine what
information they are required to submit, and familiarize themselves
with the means and format for submitting the required information.

DATES: For fiscal year 2013, identification information must be
submitted by December 3, 2012. For each subsequent fiscal year,
identification information must be submitted, updated, or reconfirmed
on or before June 1 of the preceding fiscal year.

ADDRESSES: Electronic tools for submitting the required information may
be found at the following Web sites:
     eSubmitter tool: http://www.fda.gov/ForIndustry/FDAeSubmitter/ucm108165.htm.
     Structured Product Labeling (SPL) Xforms: http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm189651.htm.
    Step-by-step instructions for electronically creating, validating,
and submitting self-identification information are available at
www.fda.gov/gdufa. Technical specifications for self-identification are
also available at www.fda.gov/gdufa. Once finalized, the file should be
transmitted to FDA through the Electronic Submissions Gateway (ESG),
FDA's electronic information portal. Information on the ESG is
available at http://www.fda.gov/ForIndustry/ElectronicSubmissionsGateway/default.htm.

FOR FURTHER INFORMATION CONTACT:  Jaewon Hong, Center for Drug
Evaluation and Research (HFD-300), Food and Drug Administration, 10903
New Hampshire Ave., Silver Spring, MD 20993-0002, 1-866-405-5367 or
301-796-6707.

SUPPLEMENTARY INFORMATION: On July 9, 2012, GDUFA (FDASIA, Title III)
(Pub. L. 112-144, Title III) was signed into law by the President.
GDUFA requires that generic drug facilities, and certain sites and
organizations identified in a generic drug submission, provide
identification information annually to FDA. This notice specifies who
is required to self-identify, the type of information to be submitted,
the means and format for submission of this information, and the
penalty for failing to comply. Additional information is contained in
the draft guidance for industry entitled ``Self-Identification of
Generic Drug Facilities, Sites and Organizations'' available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. This self-identification information will assist in
constructing an accurate inventory of facilities, sites and
organizations involved in the manufacture of generic drugs. Among other
things, the identification information may be used by FDA for purposes
including setting fee amounts and targeting inspections.

I. Who is required to self-identify?

    The following types of generic industry facilities, sites, and
organizations are required to be identified to FDA:
    1. Facilities identified, or intended to be identified in at least
one generic drug submission that is pending or approved to produce a
finished dosage form (FDF) of a human generic drug or an active
pharmaceutical ingredient (API) contained in a human generic drug.
Thus, facilities engaged in manufacturing or processing a generic API
or FDF must be identified. For purposes of self-identification and
payment of fees, GDUFA defines API and FDF manufacturers differently
from the way they have been defined historically. The GDUFA definitions
are included in the draft guidance for industry entitled ``Self-
Identification of Generic Drug Facilities, Sites and Organizations,''
available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
    2. Sites and organizations that package the FDF of a human generic
drug into the primary container/closure system and label the primary
container/closure system. Sites and organizations that package the FDF
of a human generic drug into the primary container/closure system and
label the primary

container/closure system are considered to be manufacturers, whether or
not that packaging is done pursuant to a contract or by the applicant
itself.
    3. Sites that are identified in a generic drug submission and
pursuant to a contract with the applicant remove the drug from a
primary container/closure system and subdivide the contents into a
different primary container/closure system (contract repackagers).
    4. Bioequivalence (BE)/bioavailability (BA) sites that are
identified in a generic drug submission and conduct clinical BE/BA
testing (i.e., clinical research organizations), bioanalytical testing
of samples collected from clinical BE/BA testing, and/or in vitro BE
testing.
    5. Sites that are identified in a generic drug submission and
perform testing of one or more attributes or characteristics of the FDF
or the API pursuant to a contract with the applicant to satisfy a
current good manufacturing practice testing requirement (excluding
sites that are testing for research purposes only).

II. What type of information must be submitted?

    The information required to be submitted is identified in GDUFA SPL
Industry Technical Specification Information document available at
www.fda.gov/gdufa. Note that the name and contact information for both
the registrant owner and the facility, if they are different, must be
submitted. This information includes the type of business operation,
and, if applicable, the Data Universal Numbering System (DUNS)
number(s) and the Facility Establishment Identifier (FEI). A DUNS
number is a unique nine-digit sequence provided by Dun & Bradstreet,
Inc. An FEI is a unique identifier designated by FDA to assign,
monitor, and track inspections of regulated firms. Business entities
will also be asked if they manufacture drugs other than generics.
    A facility or site that has previously registered with FDA (under
section 510 of the Federal Food, Drug, and Cosmetic Act or section 351
of the Public Health Service Act), can verify its DUNS number(s) and
FEI(s) on FDA's registration site for drug establishments available at
http://www.accessdata.fda.gov/scripts/cder/drls/default.cfm.
Information on obtaining a DUNS number or FEI(s) is provided in the
draft guidance for industry entitled ``Self-Identification of Generic
Drug Facilities, Sites and Organizations,'' available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. FDA encourages business entities to obtain the necessary
information as soon as possible to avoid delay.

III. What is the means and format for submission?

    The new electronic self-identification process will be familiar to
many business entities who have previously submitted information to FDA
electronically. Self-identification files should be formatted in the
same electronic messaging standard used for drug registration and
listing information and for the content of labeling for abbreviated new
drug applications (ANDAs). This standard known as Health Level Seven
SPL allows information to be exchanged, searched, and combined with
other data sources in a manner that supports health information
technology initiatives to improve patient care.
    The required information may be submitted using any of the
following tools to generate a self-identification SPL file:
    1. eSubmitter tool, a free stand-alone application available at
http://www.fda.gov/ForIndustry/FDAeSubmitter/ucm108165.htm. Step-by-
step instructions for electronically creating, validating, and
submitting self-identification information through eSubmitter are
available in ``eSubmitter Quick Guide--Generic Drug Facility Self-
Identification'' available at http://www.fda.gov/ForIndustry/FDAeSubmitter/ucm274477.htm; or
    2. Xforms, a free tool for generating SPL files available at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm189651.htm. Step-by-step instructions for electronically creating,
validating, and submitting self-identification information using Xforms
are available at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm; or
    3. Software tools developed internally by generic manufacturers
utilizing the SPL technical specifications. Additional information is
available at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm.
    4. Other commercially available applications (e.g., vendor tools).
    Once a self-identification SPL file is created and finalized,
transmit the file to FDA through the ESG, FDA's electronic information
portal. More information on ESG procedures and process is available on
the Electronic Submission Gateway Web site (http://www.fda.gov/ForIndustry/ElectronicSubmissionsGateway/default.htm).

IV. What is the penalty for failing to self-identify?

    Under GDUFA, if a facility fails to self-identify, all FDF or API
products manufactured at the facility and all FDFs containing APIs
manufactured at the facility will be deemed misbranded. It is a
violation of Federal law to ship misbranded products in interstate
commerce or to import them into the United States. Such a violation can
result in prosecution of those responsible, injunctions, or seizures of
the misbranded products. Products that are deemed misbranded because of
failure of the facility to self-identify are subject to being denied
entry into the United States.

    Dated: September 28, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012-24326 Filed 10-1-12; 8:45 am]
BILLING CODE 4160-01-P


[Federal Register Volume 86, Number 180 (Tuesday, September 21, 2021)]
[Notices]
[Pages 52534-52536]
[FR Doc No: 2021-20334]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-93003; File No. SR-NASDAQ-2021-070]

Self-Regulatory Organizations; The Nasdaq Stock Market LLC;
Notice of Filing and Immediate Effectiveness of Proposed Rule Change To
Incorporate NOM Options 4 Rules by Reference to Nasdaq ISE, LLC Options
4 Rules

September 15, 2021.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Act''),\1\ and Rule 19b-4 thereunder,\2\ notice is hereby given that
on September 3, 2021, The Nasdaq Stock Market LLC (``Nasdaq'' or
``Exchange'') filed with the Securities and Exchange Commission
(``SEC'' or ``Commission'') the proposed rule change as described in
Items I, II, and III, below, which Items have been prepared by the
Exchange. The Commission is publishing this notice to solicit comments
on the proposed rule change from interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The Exchange proposes to incorporate The Nasdaq Options Market LLC
(``NOM'') Options 4 Rules by reference to Nasdaq ISE, LLC (``ISE'')
Options 4 Rules.
    The text of the proposed rule change is available on the Exchange's
website at https://listingcenter.nasdaq.com/rulebook/nasdaq/rules, at
the principal office of the Exchange, and at the Commission's Public
Reference Room.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the Exchange included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. The Exchange has prepared summaries, set forth in
sections A, B, and C below, of the most significant aspects of such
statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    The NOM Options 4 Listing Rules provide for the options that may be
listed and traded on NOM. The Exchange proposes to incorporate the NOM
Options 4 Rules by reference to Nasdaq ISE, LLC (``ISE'') Options 4
Rules.
    Currently, the NOM Options 4 Rules are very similar to the ISE
Options 4 Rules. The differences between the NOM and ISE Options 4
Rules are non-substantive technical differences.\3\ Other changes are
non-substantive word choice differences.\4\ Finally, certain rules
utilize the phrase ``this Rule'' instead of a citation.\5\ Of note, NOM
Options 4, Section 3(h) does not list reverse repurchase agreements in
the defined term ``Financial Instruments''. The Exchange proposes to
include ``reverse repurchase agreements'' within the list of securities
deemed appropriate for options trading on NOM in order that the
Exchange may list the same products as ISE may list today. Also, NOM
Options 4, Section 8(a) should include the words ``and continuity.''
NOM's continuity rules utilize the LEAP

term. ISE has this rule text within its Options 4, Section 8(a).
---------------------------------------------------------------------------

    \3\ NOM Options 4, Section 2 has an extra ``as''. NOM Options 4,
Section 3(a)(1) contains a ``The'' instead of ``the.'' NOM Options
4, Section 3(b) uses the term ``foregoing'' as compared to
``forgoing'' on ISE. NOM Options 4, Section 3(h) defines the term
``NMS stock'' whereas ISE defines the term ``NMS.'' NOM Options 4,
Section 3(k)(1)(B) has an extra ``this.'' The term ``such'' within
NOM Options 4, Section 4(f)(5) is lowercase. The title
``Supplementary Material to Options 4, Section 6'' within Options 4,
Section 4 should instead state, ``Supplementary Material to Options
4, Section 4.'' NOM Options 4, Section 5(a) has an extra ``by the
Exchange.'' NOM Options 4, Section 5(b) has a ``the'' and ISE
Options 4, Section 5(b) has a ``that.'' Options 4, Section 5(e) has
a lowercase ``rule'' and unlike the same rule in ISE does not have
the registered trademarks. NOM Supplementary .01(a) to Options 4,
Section 5 uses ``$50'' instead of ``$50.00,'' has the term
``option'' instead of ``options,'' spells out ``one hundred fifty''
and incorrectly uses the term ``LEAPS'' instead of ``LEAPs.'' NOM
Supplementary .01(b) to Options 4, Section 5 has the terms
``security'' instead of ``stock'' and ``the'' instead of ``its.''
NOM Supplementary .01(d) to Options 4, Section 5 uses the term
``Strike Program'' instead of ``Strike Price Program;'' uses an
extra ``the''; and phrases the last paragraph as, ``Notwithstanding
the above delisting policy, the Exchange may grant member requests
to add strikes and/or maintain strikes in series of options classes
traded pursuant to the $1 Strike Program that are eligible for
delisting.'' The last paragraph of ISE Supplementary .01(d) to
Options 4, Section 5 states, ``Notwithstanding the above delisting
policy, Member requests to add strikes and/or maintain strikes in
series of options classes traded pursuant to the $1 Strike Price
Interval Program that are eligible for delisting may be granted.''
These differences are non-substantive. NOM Supplementary .02(d) to
Options 4, Section 5 has the term ``section'' instead of ``Rule.''
NOM Supplementary .03(e) to Options 4, Section 5 has rule in
lowercase. NOM Options 4, Section 6(a) uses a different phrase than
ISE Options 4, Section 6(a), ``Select provisions of the OLPP''
versus ``The provisions set forth in this Rule''. This
aforementioned difference is non-substantive. NOM Options 4, Section
6(b)(3) uses the term ``options'' instead of ``option.'' NOM Options
4, Section 6(b)(ii)(1) uses the term ``options'' instead of
``option,'' the term ``Strike Program'' instead of ``Strike Price
Interval Program'' and, ``rules'' instead of ``Rules.'' NOM Options
4, Section 9 uses the term ``Fund Shares'' instead of ``Exchange-
Traded Fund Shares.''
    \4\ NOM Options 4, Section 4(b)(5) should cite to ``Options 4,
Section 3(c)'' instead of ``Options 4, Section 3.'' In addition, NOM
Options 4, Section 4(b)(5) has two stray commas. NOM Options 4,
Section 4(f) has an extra ``in''. NOM Options 4, Section 4(g)(2) has
an extra ``of Options 4'' and two stray commas. NOM Options 4,
Section 5(d) incorrectly cites to Section 3(i) instead of Section
3(h). NOM Options 4, Section 6(b) incorrectly cites to Section 3(i)
instead of Section 3(h). NOM Options 4, Section 6(b)(i) incorrectly
cites to Supplementary Material .03(d) instead of Supplementary
Material .02(d). This paragraph also uses the term ``options''
instead of ``option.''
    \5\ See NOM Options 4, Section 3(c)(2). NOM utilizes citations
to Options 4, Section 3(b)(1) and Options 4, Section 3(b)(2) instead
of simply citing to ``this Rules'' as is the case with ISE Options
4, Section 3(c)(2). Other examples include NOM Options 4, Section
3(c)(3) which cites to Options 4, Section 3(b)(4), NOM Options 4,
Section 3(c)(4)(B)(ii) which cites to Options 4, Section 3(b)(5)(i).
---------------------------------------------------------------------------

    The Exchange proposes to incorporate by reference the NOM Options 4
Rules to ISE Options 4 Rules. To that end, NOM proposes to replace the
current NOM Options 4 Rules with the following rule text:

    The rules contained in Nasdaq ISE Options 4, as such rules may
be in effect from time to time (the ``Options 4 Rules''), are hereby
incorporated by reference into this NOM Options 4, and are thus NOM
Rules and thereby applicable to NOM Participants. NOM Participants
shall comply with the Options 4 Rules as though such rules were
fully set forth herein. All defined terms, including any variations
thereof, contained in the Options 4 Rules shall be read to refer to
the NOM related meaning of such term. Solely by way of example, and
not in limitation or in exhaustion: The defined term ``Exchange'' in
the Options 4 Rules shall be read to refer to NOM; the defined term
``Rule'' in the Options 4 Rules shall be read to refer to the NOM
Rule; the defined terms ``Competitive Market Maker'' and ``Market
Maker'' in the Options 4 Rules shall be read to refer to the NOM
Market Maker (NOM does not have an equivalent to the ``Lead Market
Maker'' term on ISE); and the defined terms ``Electronic Access
Member,'' ``EAM,'' or ``Member'' in the Options 4 Rules shall be
read to refer to the NOM Participant.

    This rule text will account for differences that may exist in the
usage of terms as between NOM and ISE. The proposed rule text list
instances in which cross references in the ISE Options 4 Rules to NOM
Options 4 Rules shall be read to refer instead to the Exchange Rules,
and references to ISE terms (whether or not defined) shall be read to
refer to the Exchange-related meanings of those terms. For instance,
references to defined terms ``Exchange'' or ``ISE'' shall be read to
refer to ISE.
    The Exchange proposes to delete in their entirety the NOM Options 4
Rules and incorporate by reference the ISE Options 4 Rules.\6\ Today,
the rules of Nasdaq GEMX, LLC and Nasdaq MRX, LLC are incorporated by
reference to the rules of ISE. The Exchange will also separately file
to incorporate the Options 4 Rules of Nasdaq BX, Inc. and Nasdaq Phlx
LLC to the ISE Options 4 Rules once those exchanges conform those
rules, respectively, to ISE. The Exchange believes that harmonizing the
Options 4 Rules across its 6 Nasdaq Affiliated Options Exchanges will
assist the Exchange in listing options across its affiliated markets.
Also, incorporating by reference the ISE Options 4 Rules into the
Exchange's rulebook will organize those listing rules in a more logical
order, thereby eliminating unnecessary complexity in the listing
process and otherwise streamlining the Exchange's existing listing
rules and their associated procedures.
---------------------------------------------------------------------------

    \6\ The Exchange will separately request an exemption from the
rule filing requirements of Section 19(b) of the Act for changes to
NOM Options 4 Rules to the extent such rules are affected solely by
virtue of a change to ISE Options 4 Rules. The Exchange's proposed
rule change will not become effective unless and until the
Commission grants this exemption request.
---------------------------------------------------------------------------

2. Statutory Basis
    The Exchange believes that its proposal is consistent with Section
6(b) of the Act,\7\ in general, and furthers the objectives of Section
6(b)(5) of the Act,\8\ in particular, in that it is designed to promote
just and equitable principles of trade and to protect investors and the
public interest. The Exchange believes that its proposal to delete its
existing listing rules and incorporate by reference the ISE Options 4
Rules will promote a free and open market, and will benefit investors,
the public, and the markets, because the new rules will be clearer,
better organized, and simpler. Also, the proposal is just and equitable
because it will render the Exchange's listing rules easier for
Participants to read and understand.
---------------------------------------------------------------------------

    \7\ 15 U.S.C. 78f(b).
    \8\ 15 U.S.C. 78f(b)(5).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change will
impose any burden on competition not necessary or appropriate in
furtherance of the purposes of the Act. The Exchange does not expect
that its proposed changes to incorporate NOM's Options 4 Rules to ISE's
Options 4 Rules will have any competitive impact on NOM's listing
rules, to the contrary, the Exchange hopes that by clarifying,
reorganizing, and streamlining its listing rules, the Exchange's
listing process will be clear. The proposed changes will apply equally
to all market participants.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants, or Others

    No written comments were either solicited or received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    Because the foregoing proposed rule change does not: (i)
Significantly affect the protection of investors or the public
interest; (ii) impose any significant burden on competition; and (iii)
become operative for 30 days from the date on which it was filed, or
such shorter time as the Commission may designate, it has become
effective pursuant to Section 19(b)(3)(A)(iii) of the Act \9\ and
subparagraph (f)(6) of Rule 19b-4 thereunder.\10\
---------------------------------------------------------------------------

    \9\ 15 U.S.C. 78s(b)(3)(A)(iii).
    \10\ 17 CFR 240.19b-4(f)(6). In addition, Rule 19b-4(f)(6)
requires a self-regulatory organization to give the Commission
written notice of its intent to file the proposed rule change at
least five business days prior to the date of filing of the proposed
rule change, or such shorter time as designated by the Commission.
The Exchange has satisfied this requirement.
---------------------------------------------------------------------------

    At any time within 60 days of the filing of the proposed rule
change, the Commission summarily may temporarily suspend such rule
change if it appears to the Commission that such action is necessary or
appropriate in the public interest, for the protection of investors, or
otherwise in furtherance of the purposes of the Act. If the Commission
takes such action, the Commission shall institute proceedings to
determine whether the proposed rule should be approved or disapproved.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's internet comment form (http://www.sec.gov/rules/sro.shtml); or
     Send an email to<EMAIL_ADDRESS>Please include
File Number SR-NASDAQ-2021-070 on the subject line.

Paper Comments

     Send paper comments in triplicate to Secretary, Securities
and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.

All submissions should refer to File Number SR-NASDAQ-2021-070. This
file number should be included on the subject line if email is used. To
help the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's internet website (http://www.sec.gov/rules/sro.shtml).
Copies of the submission, all subsequent amendments, all written
statements with respect to the proposed rule change that are filed with
the Commission, and all written communications relating to the proposed
rule change between the Commission and any person, other than

those that may be withheld from the public in accordance with the
provisions of 5 U.S.C. 552, will be available for website viewing and
printing in the Commission's Public Reference Room, 100 F Street NE,
Washington, DC 20549, on official business days between the hours of
10:00 a.m. and 3:00 p.m. Copies of the filing also will be available
for inspection and copying at the principal office of the Exchange. All
comments received will be posted without change. Persons submitting
comments are cautioned that we do not redact or edit personal
identifying information from comment submissions. You should submit
only information that you wish to make available publicly. All
submissions should refer to File Number SR-NASDAQ-2021-070 and should
be submitted on or before October 12, 2021.

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\11\
---------------------------------------------------------------------------

    \11\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

J. Matthew DeLesDernier,
Assistant Secretary.
[FR Doc. 2021-20334 Filed 9-20-21; 8:45 am]
BILLING CODE 8011-01-P


[Federal Register Volume 76, Number 194 (Thursday, October 6, 2011)]
[Notices]
[Page 62060]
[FR Doc No: 2011-25838]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No., 14238-000]

NortHydro, LLC; Notice of Preliminary Permit Application Accepted
for Filing and Soliciting Comments, Motions To Intervene, and Competing
Applications

    On July 29, 2011, NortHydro, LLC (NortHydro or applicant) filed an
application for a preliminary permit, pursuant to section 4(f) of the
Federal Power Act (FPA), proposing to study the feasibility of the
Scooteney Wasteway Hydroelectric project (project) near Richland in
Franklin County, Washington. The wasteway was constructed by the U.S.
Bureau of Reclamation as part of the Columbia Basin Project, and is
situated within and operated by the South Columbia Basin Irrigation
District. The wasteway functions as a diversion of surplus water from
the irrigation system to the existing Scooteney reservoir. The sole
purpose of a preliminary permit, if issued, is to grant the permit
holder priority to file a license application during the permit term. A
preliminary permit does not authorize the permit holder to perform any
land-disturbing activities or otherwise enter upon lands or waters
owned by others without the owners' express permission.
    The project would collect all surplus flows below the Scooteney
wasteway outlet structure. The following new facilities are proposed:
(1) A 63-inch, 2,850-foot-long underground penstock that would collect
water from the Scooteney wasteway; (2) a powerhouse containing one
turbine/generator unit with a capacity of 1,110 kilowatts; (3) a 4.2-
mile-long, 115-kilovolt transmission line connecting to the existing
Ringold substation; and (4) appurtenant facilities. The estimated
annual generation of the project would be 4.8 gigawatt-hours.
    Applicant Contact: Mr. Darius Ruen, P.E., NortHydro, LLC, 3201
Huetter Road, Suite 102, Coeur d'Alene, Idaho 83814; phone (208) 292-
0820.
    FERC Contact: Patrick Murphy; phone<PHONE_NUMBER>.
    Deadline for Filing Comments, Motions to Intervene, Competing
Applications (Without Notices of Intent), or Notices of Intent to File
Competing Applications: 60 days from the issuance of this notice.
Competing applications and notices of intent must meet the requirements
of 18 CFR 4.36. Comments, motions to intervene, notices of intent, and
competing applications may be filed electronically via the Internet.
See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's
Web site http://www.ferc.gov/docs-filing/efiling.asp. Commenters can
submit brief comments up to 6,000 characters, without prior
registration, using the eComment system at http://www.ferc.gov/docs-filing/ecomment.asp. You must include your name and contact information
at the end of your comments. For assistance, please contact FERC Online
Support at<EMAIL_ADDRESS>or toll free at 1-866-208-3676,
or for TTY,<PHONE_NUMBER>. Although the Commission strongly encourages
electronic filing, documents may also be paper-filed. To paper-file,
mail an original and seven copies to: Kimberly D. Bose, Secretary,
Federal Energy Regulatory Commission, 888 First Street, NE.,
Washington, DC 20426.
    More information about this project, including a copy of the
application, can be viewed or printed on the ``eLibrary'' link of
Commission's Web site at http://www.ferc.gov/docs-filing/elibrary.asp.
Enter the docket number (P-14238-000) in the docket number field to
access the document. For assistance, contact FERC Online Support.

    Dated: September 29, 2011.
Kimberly D. Bose,
Secretary.
[FR Doc. 2011-25838 Filed 10-5-11; 8:45 am]
BILLING CODE 6717-01-P